Kamada (KMDA): NIH begs to differ on FDA's EUA for...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	145
Posts	27558
Boards Moderated	3
Alias Born	02/07/2004

midastouch017

Re: None

Wednesday, 09/02/2020 8:49:46 AM

Wednesday, September 02, 2020 8:49:46 AM

NIH begs to differ on FDA's EUA for convalescent plasma for COVID-19

Sep. 1, 2020 3:48 PM ET|About: Kamada Ltd. (KMDA)|By: Stephen Alpher, SA News Editor

"Convalescent plasma should not be considered standard of care for the treatment of patients with COVID-19," says the NIH. "There are currently no data from well-controlled, adequately powered randomized clinical trials that demonstrate the efficacy and safety of convalescent plasma for the treatment of COVID-19."

More: "There are insufficient data to recommend either for or against the use of convalescent plasma for the treatment of COVID-19 ... Prospective, well-controlled, adequately powered randomized trials are needed to determine whether convalescent plasma is effective and safe for the treatment of COVID-19."

Backed by the president, the FDA last week granted emergency use authorization for the treatment.

Related names: Kamada (KMDA -6.6%)

https://seekingalpha.com/news/3610697-nih-begs-to-differ-on-fdas-eua-for-convalescent-plasma-for-covidminus-19